(Q39026376)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

acute myeloid leukemia

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sarah Tettamanti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

I Pizzitola

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Anjos-Afonso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Lassailly

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

O Spinelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A Biondi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E Biagi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Bonnet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

7 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1596-1605

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24504024%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.62

7 March 2020

exact match

0 references

cites work

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Recent advances in acute myeloid leukemia stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

12 December 2020

Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy

1 reference

12 December 2020

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

1 reference

12 December 2020

Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist

1 reference

12 December 2020

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

1 reference

12 December 2020

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production

1 reference

12 December 2020

Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells in CLL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.62

7 January 2021